Aromatase Inhibitor

10 Drugs classified under this drug class

Aromatase Inhibitor. Anastrozole 1 mg.
F.C. TAB: 30. Not recommend. in child.
Adults, includ. elderly: 1 tab 1 x dly.
Mild/mod. ren. impair: No dose
change. Mild hepat. impair: No dose
change.
Tmt. advanced breast cancer in
postmenopaus. women. Efficacy not
demonstrat. in estrogen recept. neg. pts
unless with prev. +ive. clin. response to
tamoxifen; adjuv. tmt. postmenopaus.
women with hormone recept. +ive early
invas. breast cancer; adjuv. tmt. early
breast cancer in hormone recept. +ive
postmenopaus. women who have
received 2-3 yrs adjuv. tamoxifen.
C/I: Pre-menopaus. women; pregn.,
lactat., severe renal impair. (creatin.
clearance < 20 ml/min.); mod.-severe
hepat. dis; known hypersens., co-admin
of estrogen-contain. ther./tamoxifen
ther.

Aromatase Inhibitor. Anastrozole 1 mg.
TAB: 30. Not recommend. in child.
Adults, includ. elderly: 1 mg 1 x dly.
Mild/mod. ren. impair: No dose
change. Mild hepat. impair: No dose
change.
Tmt. advanced breast cancer in
postmenopaus. women. Efficacy not
demonstrat. in estrogen recept. neg. pts
unless with prev. pos. clin. response to
tamoxifen; adjuv. tmt. postmenopaus.
women with hormone recept. +ive early
invas. breast cancer; adjuv. tmt. early
breast cancer in hormone recept. +ive
postmenopaus. women who have
received 2-3 yrs adjuv. tamoxifen.
C/I: Pre-menopaus. women; pregn.,
lactat., severe renal impair. (creatin.
clearance < 20 ml/min.); mod.-severe
hepat. dis; known hypersens., co-admin
of estrogen-contain. ther./tamoxifen
ther.

Aromatase Inhibitor. Anastrozole 1 mg.
TABS: 28. Adults and elderly: 1 tab. dly.
Advanced breast cancer in post-menopaus.
women. Adjuv. tmt of
postmenopaus. women with hormone
receptor-positive early invasive breast
cancer. Adjuv. tmt. early breast cancer in
hormone receptor +tive postmenopaus.
women who have received 2-3 yrs.
adjunct. tamoxifen.
C/I: Severe ren. impair., mod. or severe
hepat. dis., pregn., lact.

Aromatase Inhibitor. Exemestane 25 mg.
TABS: 30. 1 tab (25 mg) dly. aft. meals.
See lit.
Advanced breast cancer (ABC) in women
with natural/induced post-menopaus.
status (progress. foll. anti-estrogen ther.
alone) and in post-menopaus. women
(progress. foll. multiple hormonal
therapies). Adjuv. tmt post-menopaus.
women with estrogen receptor pos. invas.
early breast cancer foll. 2-3 yrs of initial
adjuv. ther.
C/I: Hypersens., premenopaus., pregn.,
lact.

Aromatase Inhibitor. Exemestane 25 mg.
COAT. TABS.:30. One tab. (25 mg)×1/d. See lit.
Tmt. of advanced breast cancer (ABC) in women with natural or induced postmenopaus. status whose disease has progres. follow. anti-oestrogen ther. alone. Tmt. of postmenopaus. women with ABC whose dis. has progres. follow. multiple hormone. therapies.
Indicated for the adjuvant tmt. of postmenopaus. women with oestrogen receptor positive invas. early breast cancer follow. 2-3 years of init. adjuvant tamoxifen ther.
C/I: Hypersens. Pregnancy. Lactation.
Women of child bear. potential.

Aromatase Inhibitor. Exemestane 25 mg.
F.C.TABS: 25 mg: x 10, 14, 15, 20, 28, 30,
50, 60, 90, 98, 100, 120 tab.
1 tab (25 mg) dly. aft. meals.
Tmt. of advanced breast cancer (ABC) in
women with nat./ induc. postmenopaus.
status (progress. foll. anti-estrogen ther.
alone); Tmt. of postmenopaus. women
with ABC whose disease has progress. foll.
multiple hormonal ther. Adjuv. tmt. of postmenopaus. women with estrogen
receptor pos. invas. early breast cancer foli.
2-3 years of initial adjuv. tamoxifen ther.
C/I: Hypersens., premenopaus., pregn.,
lact.